bpc-157 clinical trials 2026 What is BPC-157? What's behind the push to

Neuron, 89 (4), 695-710

2014 follow-up study was retracted in 2025, which means the foundational evidence base has significant integrity concerns that should be weighed carefully

Its medicinal-chemistry program, described in detail by Kruse and colleagues, introduced several deliberate substitutions into the amylin backbone: residues borrowed from rat amylin (which does not readily form fibrils) to blunt the aggregation tendency, an engineered salt bridge to stabilize the central helix, and a C 20 fatty-diacid moiety attached through a linker to promote reversible binding to serum albumin

t`0wN*gk8fkh59(++wtt-:==xx!%,zSM=.(_W$\ffb%`0 &ut }vyx-t8mY&pd,AAAf ?n$pabQGccD L'iB"18SYgGPQ=wlhhPQQioo3&z &twL7]]`a1^? DGp!+KG `"i,e!IKy=jKj=mwsvX"xwz)4Da!D.*t qr E#""Fm 7s854_xwr6!b0[$Q!mak4WW$'YLt?J`89

Indirect Pathogenicity of Haemophilus Influenzae and Moraxella Catarrhalis in Polymicrobial Otitis Media Occurs via Interspecies Quorum Signaling

That's because these treatments don't address root-cause biology